Author: Louis Navellier and the InvestorPlace Research Staff

These names are the next generation of biotechs that will influence 21st Century medicine.

Thanks to its high quality, reasonable valuation and still-strong prospects, it remains a name to hold for the long haul.

A long-term position could serve you well as U.S. legislation could buoy the stock in the coming months and years.

If you’re building a nest egg, then you really need to include some solid dividend stocks for durability and solid, steady growth. Here are some names to consider.